Antibiotic Collaboration and Licensing Deals 2016-2026

Description

The definitive benchmark for antibiotic dealmaking

Antibiotic partnering is shaped by the growing challenge of antimicrobial resistance, with deal structures reflecting the unique scientific, regulatory, and commercial dynamics of developing anti-infective therapies.

This report provides a comprehensive and structured analysis of 140+ antibiotic collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how antibiotic deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by development stage, mechanism of action, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a scientifically critical and economically distinct therapeutic landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within antibiotic partnerships, particularly in areas influenced by public health priorities and non-traditional commercial models.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark anti-infective transactions
Prepare for negotiations with well-defined market context
Evaluate partnership opportunities and counterparties
Support internal strategy with robust, defensible data
What's included
140+ antibiotic collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, mechanism, and development stage)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for antibiotic dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how antibiotic partnerships are structured, negotiated, and valued.

Product Code: CP2119

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibiotic dealmaking

2.1. Introduction
2.2. Antibiotic deals over the years
2.3. Most active antibiotic dealmakers
2.4. Antibiotic deals by deal type
2.5. Antibiotic deals by therapy area
2.6. Antibiotic deals by industry sector
2.7. Deal terms for antibiotic deals
- 2.7.1 Antibiotic deals headline values
- 2.7.2 Antibiotic deal upfront payments
- 2.7.3 Antibiotic deal milestone payments
- 2.7.4 Antibiotic royalty rates

Chapter 3 - Leading antibiotic deals

3.1. Introduction
3.2. Top antibiotic deals by value

Chapter 4 - Most active antibiotic dealmakers

4.1. Introduction
4.2. Most active antibiotic dealmakers
4.3. Most active antibiotic deals company profiles

Chapter 5 - Antibiotic contracts dealmaking directory

5.1. Introduction
5.2. Antibiotic contracts dealmaking directory

Chapter 6 - Antibiotic dealmaking by technology type

Deal directory
Deal directory - Antibiotic deals by company A-Z
Deal directory - Antibiotic deals by deal type
Deal directory - Antibiotic deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Antibiotic deals since 2016
Figure 2: Active antibiotic dealmaking activity since 2016
Figure 3: Antibiotic deals by deal type since 2016
Figure 4: Antibiotic deals by therapy area since 2016
Figure 5: Antibiotic deals by industry sector since 2016
Figure 6: Antibiotic deals with a headline value
Figure 7: Antibiotic deals with an upfront value
Figure 8: Antibiotic deals with a milestone value
Figure 9: Antibiotic deals with a royalty rate value
Figure 10: Top antibiotic deals by value since 2016
Figure 11: Most active antibiotic dealmakers since 2016
Figure 12: Antibiotic deals by technology type since 2016